DexCom, Inc. (DXCM)
DexCom slashes full-year sales forecast, shares plummet
DexCom Inc (NASDAQ:DXCM, ETR:DC4), a medical device maker that produces continuous glucose monitoring systems for diabetes management, shares plunged by more than 40% after the company slashed its annual revenue forecast. The company now expects full-year revenue of $4 billion to $4.05 billion, representing organic growth between 11% and 13%, down from its earlier forecast of $4.2 billion to $4.35 billion.
DexCom, Inc. (DXCM) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of DexCom, Inc. ("DexCom") (NASDAQ:DXCM) concerning possible violations of federal securities laws. After the closure of market trading, on July 25, 2024, DexCom issued a press release announcing its financial results for the second quarter of 2024.
Why DexCom Stock Is Crashing Today
DexCom reported mixed Q2 results with an earnings beat, but revenue missed expectations. The company lowered its full-year revenue guidance.
Dexcom (DXCM) Stock Is Plunging on an ‘Execution Miss.' What Is Really Going On?
Dexcom (NASDAQ: DXCM ) stock is down over 40% after reporting disappointing revenue for the second quarter. It also lowered guidance for the rest of the year.
DexCom Stock Plunges 37% After Earnings. GLP-1s Weren't the Problem.
Shares of DexCom were spiraling after the medical device company surprised Wall Street with a steep cut to guidance.
Why Is DexCom (DXCM) Stock Down 38% Today?
DexCom (NASDAQ: DXCM ) stock is falling on Friday after the company released its earnings report for Q2 2024. DexCom starts its earnings report with adjusted earnings per share of 43 cents.
DexCom, Zynex, Olin And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Friday.
Dexcom plunges 40% after glucose monitor maker slashes sales forecast
Dexcom's shares sank about 38% in premarket trading on Friday after the medical device maker cut its annual revenue forecast, with analysts calling some of the issues 'self inflicted' rather than a broader market growth problem.
DexCom Q2: Surprising Earnings Miss With Hints Of Competitive Pressures
DexCom reported disappointing earnings, missing estimates by 4% and lowering full-year growth expectations by ~$200 million. Sales in the U.S. market slowed, while international markets saw anemic growth, impacting the company's outlook. Markets blamed sales on poor sales execution, complicated by inefficient distribution channels. Despite strong earnings, DXCM faces challenges with distribution channels and growing competition, leading to a downgrade to Hold.
Watch These Dexcom Price Levels as Stock Plunges After Guidance Slashed
Shares in Dexcom (DXCM) lost more than a third of their value in extended trading Thursday after the medical devices company posted second-quarter results that came in below Wall Street expectations and slashed its annual revenue forecast.
DexCom, Inc. (DXCM) Q2 2024 Earnings Call Transcript
DexCom, Inc. (NASDAQ:DXCM ) Q2 2024 Earnings Conference Call July 25, 2024 4:30 PM ET Corporate Participants Sean Christensen - Vice President of Finance, and Investor Relations Kevin Sayer - Chairman, President, and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Jeff Johnson - Baird Magaret Andrew - William Blair Travis Steed - Bank of America Matt Taylor - Jefferies Danielle Antalffy - UBS Joanne Wuensch - Citibank Matthew O'Brien - Piper Sandler Sam Eiber - BTIG Mathew Blackman - Stifel Jason Bedford - Raymond James Steve Lichtman - Oppenheimer Mike Polark - Wolfe Research Shagun Singh - RBC Capital Markets Bill Plovanic - Canaccord Genuity Chris Pasquale - Nephron Matt Miksic - Barclays Operator Welcome to the Dexcom Second Quarter 2024 Earnings Release Conference Call. My name is Abby and I'll be your operator for today's call.
DexCom (DXCM) Q2 Earnings Surpass Estimates
DexCom (DXCM) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.34 per share a year ago.
